Perspectives in immunotherapy of allergic diseases II. Targeting interleukin 4 (IL-4)
Article Sidebar
Published:
Jan 28, 2008
Keywords:
immunotherapy, IL-4, allergic diseases
Main Article Content
Abstract
Interleukin 4 (IL-4) is a pivotal cytokine for type I hypersensitivity reactions and allergic diseases. IL-4, among others, promotes development of Th2 lymphocytes and is critical for IgE class switching. In the paper recent trends and perspectives of blocking function of IL-4 have been described from the point of view of therapy of allergic diseases.
Downloads
Download data is not yet available.
Article Details
How to Cite
Lasek , W. (2008). Perspectives in immunotherapy of allergic diseases II. Targeting interleukin 4 (IL-4). Alergoprofil, 3(4), 2-6. Retrieved from https://journalsmededu.pl/index.php/alergoprofil/article/view/29
Issue
Section
Article
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
1. Brombacher F.: The role of interleukin-13 in infectious diseases and allergy. BioEssays 2000; 22: 646-656.
2. Cianferoni A., Schroeder J.T., Kim J. et al.: Selective inhibition of interleukin-4 gene expression in human T cells by aspirin. Blood 2001; 97: 1742-1749.
3. Dabbagh K., Takeyama K., Lee H.M. et al.: IL-4 induces mucin gene expression and goblet cell metaplasia in vitro and in vivo. J. Immunol. 1999; 162: 6233-6237.
4. Economides A.N., Rocco Carpenter L., Rudge J.S. et al.: Cytokine traps: multi-component, high-affinity blockers of cytokine action. Nature Med. 2003; 9: 47-52.
5. Gonzalez G., Crombet T., Catala M. et al.: A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: report of a pilot clinical trial. Ann. Oncol. 1998; 9: 431-435.
6. Gringeri A., Musicco M., Hermans P. et al.: Active anti-interferon-alpha immunization: a European-Israeli, randomized, double-blind, placebo-controlled clinical trial in 242 HIV-1- infected patients (the EURIS study). J. Acquir. Immune. Defic. Syndr. Human Retrovirol. 1999; 20: 358-370.
7. Haitchi H.M., Holgate S.T.: New strategies in the treatment and prevention of allergic diseases. Expert Opin. Investig. Drugs 2004; 13: 107-124.
8. Hart T.K., Blackburn M.N., Brigham-Burke M. et al.: Preclinical efficacy and safety of pascolizumab (SB 240683): a humanized anti-interleukin-4 antibody with therapeutic potential in asthma. Clin. Exp. Immunol. 2002; 130: 93-100.
9. Hennekes H., Asadullah K.: Strategies for targeting IL-4 as a novel therapeutic approach for the treatment of atopic dermatitis. Curr. Med. Chem. – Anti-Inflammatory and Anti-Allergy Agents 2002; 1: 41-53.
10. Holgate S.T.: Cytokine and anti-cytokine therapy for the treatment of asthma and allergic disease. Allergology Int. 2004; 53: 47-54.
11. Keegan A.D.: IL-4. W: Cytokine Reference vol. 1. Oppenheim J.J., Feldman M. (red.). Academic Press, San Diego 2000: 127-135.
12. Keegan A.D.: IL-4 receptor. W: Cytokine Reference vol. 2. Oppenheim J.J., Feldman M. (red.). Academic Press, San Diego 2000: 1471-1480.
13. König B., Fischer A., König W.: Modulation of cell-bound and soluble CD23, spontaneous and ongoing IgE synthesis of human peripheral blood mononuclear cells by soluble IL-4 receptors and the partial antagonistic IL-4 mutant protein IL-4 (Y124D). Immunology 1995; 85: 604-610.
14. La Porte S.L., Forsyth C.M., Cunningham B.C. et al.: De novo design of an IL-4 antagonist and its structure at 1.9 Ĺ. Proc. Natl. Acad. Sci. USA 2005; 102: 1889-1894.
15. Li-Weber M., Krammer P.H.: Regulation of IL4 gene expression by T cells and therapeutic perspectives. Nature Rev. Immunol. 2003; 3: 534-543.
16. Ma Y., Hayglass K.T., Becker A.B. et al.: Novel cytokine peptide-based vaccines: an interleukin-4 vaccine suppress airway allergic responses in mice. Alergy 2007; 62: 675-682.
17. Nagashima S., Yokota M., Nakai E. et al.: Synthesis and evaluation of 2-{[2-(4-hydroxyphenyl) ethyl]amino}pyrimidine5-carboxamide derivatives as novel STAT6 inhibitors. Bioorg. Medicin. Chem. 2007; 15: 1044-1055.
18. Parsey M., Fauci G., Dunn J. et al.: Human pharmacokinetic evaluation of the IL-4/13 trap : a novel immunomodulatory agent for the treatment of HIV disease. 11th Conference Retrovir Opportunistic Infect, Febr 8-11, 2004, abstract 522.
19. Sakurai M., Nishio M., Yamamoto K. et al.: TMC-264, a novel antiallergic heptaketide produced by the fungus Phoma sp. TC 1674. Org. Lett. 2003; 5: 1083-1085.
20. Shanafelt A.B., Forte C.P., Kasper J.J. et al.: An immune cellselective interleukin 4 agonist. Proc Natl. Acad. Sci. USA 1998; 95: 9454-9458.
21. Sunesis Pharm. Inc.: WO0198245: Small molecule IL-4 antagonists. Expert Opin. Ther. Patents 2002; 12: 1103-1105.
22. Tamaoki J., Kondo M., Sakai N. et al.: Effect of suplatast tosilate a Th2 cytokine inhibitor, on steroid dependent astma – a double-blind randomised study. Lancet 2000; 356: 373-378.
23. Tohda Y., Nakahara H., Kubo H. et al.: Theophylline suppresses the release of interleukin-4 by peripheral blond mononuclear cells. Int. Arch. Allergy Immunol. 1998; 115: 42-46.
24. Tsitoura D.D., Tarsios Y.: Immunomodulation in the future cure for allergic diseases. Ann. N.Y. Acad. Sci. 2006; 1088: 100-115.
25. Ward M.: Breathless opportunities. BioCentury, the Bernstein report on biobusiness, Feb. 6, 2006: 1-7.
26. Yokozeki H., Wu M.-H., Sumi K. et al. In vivo transfection of a cis element ‘decoy’ against signal transducers and activation of transcription 6 (STAT6)-binding site ameliorates IgEmediated late-phase reaction in an atopic dermatitis mouse model. Gene. Ther. 2004; 11: 1753-1762.
27. Online: http://clinicaltrials.gov/ct/show/NCT00024544 (Access: 9.07.2007).
28. Online: http://www.freepatentsonline.com/EP1501796.html (Access: 10.09.2007).
29. Online: http:/www.aerovance.com/aer001.html (Access: 10.09.2007).
30. Online: http://clinicaltrials.gov/ct/show/NCT00436670 (Access: 10.09.2007) .
2. Cianferoni A., Schroeder J.T., Kim J. et al.: Selective inhibition of interleukin-4 gene expression in human T cells by aspirin. Blood 2001; 97: 1742-1749.
3. Dabbagh K., Takeyama K., Lee H.M. et al.: IL-4 induces mucin gene expression and goblet cell metaplasia in vitro and in vivo. J. Immunol. 1999; 162: 6233-6237.
4. Economides A.N., Rocco Carpenter L., Rudge J.S. et al.: Cytokine traps: multi-component, high-affinity blockers of cytokine action. Nature Med. 2003; 9: 47-52.
5. Gonzalez G., Crombet T., Catala M. et al.: A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: report of a pilot clinical trial. Ann. Oncol. 1998; 9: 431-435.
6. Gringeri A., Musicco M., Hermans P. et al.: Active anti-interferon-alpha immunization: a European-Israeli, randomized, double-blind, placebo-controlled clinical trial in 242 HIV-1- infected patients (the EURIS study). J. Acquir. Immune. Defic. Syndr. Human Retrovirol. 1999; 20: 358-370.
7. Haitchi H.M., Holgate S.T.: New strategies in the treatment and prevention of allergic diseases. Expert Opin. Investig. Drugs 2004; 13: 107-124.
8. Hart T.K., Blackburn M.N., Brigham-Burke M. et al.: Preclinical efficacy and safety of pascolizumab (SB 240683): a humanized anti-interleukin-4 antibody with therapeutic potential in asthma. Clin. Exp. Immunol. 2002; 130: 93-100.
9. Hennekes H., Asadullah K.: Strategies for targeting IL-4 as a novel therapeutic approach for the treatment of atopic dermatitis. Curr. Med. Chem. – Anti-Inflammatory and Anti-Allergy Agents 2002; 1: 41-53.
10. Holgate S.T.: Cytokine and anti-cytokine therapy for the treatment of asthma and allergic disease. Allergology Int. 2004; 53: 47-54.
11. Keegan A.D.: IL-4. W: Cytokine Reference vol. 1. Oppenheim J.J., Feldman M. (red.). Academic Press, San Diego 2000: 127-135.
12. Keegan A.D.: IL-4 receptor. W: Cytokine Reference vol. 2. Oppenheim J.J., Feldman M. (red.). Academic Press, San Diego 2000: 1471-1480.
13. König B., Fischer A., König W.: Modulation of cell-bound and soluble CD23, spontaneous and ongoing IgE synthesis of human peripheral blood mononuclear cells by soluble IL-4 receptors and the partial antagonistic IL-4 mutant protein IL-4 (Y124D). Immunology 1995; 85: 604-610.
14. La Porte S.L., Forsyth C.M., Cunningham B.C. et al.: De novo design of an IL-4 antagonist and its structure at 1.9 Ĺ. Proc. Natl. Acad. Sci. USA 2005; 102: 1889-1894.
15. Li-Weber M., Krammer P.H.: Regulation of IL4 gene expression by T cells and therapeutic perspectives. Nature Rev. Immunol. 2003; 3: 534-543.
16. Ma Y., Hayglass K.T., Becker A.B. et al.: Novel cytokine peptide-based vaccines: an interleukin-4 vaccine suppress airway allergic responses in mice. Alergy 2007; 62: 675-682.
17. Nagashima S., Yokota M., Nakai E. et al.: Synthesis and evaluation of 2-{[2-(4-hydroxyphenyl) ethyl]amino}pyrimidine5-carboxamide derivatives as novel STAT6 inhibitors. Bioorg. Medicin. Chem. 2007; 15: 1044-1055.
18. Parsey M., Fauci G., Dunn J. et al.: Human pharmacokinetic evaluation of the IL-4/13 trap : a novel immunomodulatory agent for the treatment of HIV disease. 11th Conference Retrovir Opportunistic Infect, Febr 8-11, 2004, abstract 522.
19. Sakurai M., Nishio M., Yamamoto K. et al.: TMC-264, a novel antiallergic heptaketide produced by the fungus Phoma sp. TC 1674. Org. Lett. 2003; 5: 1083-1085.
20. Shanafelt A.B., Forte C.P., Kasper J.J. et al.: An immune cellselective interleukin 4 agonist. Proc Natl. Acad. Sci. USA 1998; 95: 9454-9458.
21. Sunesis Pharm. Inc.: WO0198245: Small molecule IL-4 antagonists. Expert Opin. Ther. Patents 2002; 12: 1103-1105.
22. Tamaoki J., Kondo M., Sakai N. et al.: Effect of suplatast tosilate a Th2 cytokine inhibitor, on steroid dependent astma – a double-blind randomised study. Lancet 2000; 356: 373-378.
23. Tohda Y., Nakahara H., Kubo H. et al.: Theophylline suppresses the release of interleukin-4 by peripheral blond mononuclear cells. Int. Arch. Allergy Immunol. 1998; 115: 42-46.
24. Tsitoura D.D., Tarsios Y.: Immunomodulation in the future cure for allergic diseases. Ann. N.Y. Acad. Sci. 2006; 1088: 100-115.
25. Ward M.: Breathless opportunities. BioCentury, the Bernstein report on biobusiness, Feb. 6, 2006: 1-7.
26. Yokozeki H., Wu M.-H., Sumi K. et al. In vivo transfection of a cis element ‘decoy’ against signal transducers and activation of transcription 6 (STAT6)-binding site ameliorates IgEmediated late-phase reaction in an atopic dermatitis mouse model. Gene. Ther. 2004; 11: 1753-1762.
27. Online: http://clinicaltrials.gov/ct/show/NCT00024544 (Access: 9.07.2007).
28. Online: http://www.freepatentsonline.com/EP1501796.html (Access: 10.09.2007).
29. Online: http:/www.aerovance.com/aer001.html (Access: 10.09.2007).
30. Online: http://clinicaltrials.gov/ct/show/NCT00436670 (Access: 10.09.2007) .